AMRX Q3 2020 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMRXAmneal Pharmaceuticals, Inc.

$4B

Q3 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$519M+37.3% YoY

Gross Profit

$134M25.7% margin

Operating Income

$2M0.5% margin

Net Income

-$9M-1.7% margin

EPS (Diluted)

$-0.06

QoQ Revenue Growth

+11.8%

Cash Flow

Operating Cash Flow

$45M

Free Cash Flow

$30M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$4.0B

Total Liabilities

$3.7B

Stockholders' Equity

$301M

Cash & Equivalents

$281M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$519M	$378M	+37.3%
Gross Profit	$134M	$54M	+145.4%
Operating Income	$2M	-$112M	+102.2%
Net Income	-$9M	-$265M	+96.6%

Revenue Segments

Generics Segment

$342M66%

Av K A R E Segment

$90M17%

Amneal Specialty Pharma Segment

$88M17%